Lin Shen

Lin Shen is a leading medical oncologist in China specializing in gastrointestinal cancers, particularly gastric and colorectal cancers, and has contributed significantly to clinical research in the context of the enormous gastric cancer burden in China. His research has participated in pivotal trials establishing checkpoint immunotherapy and HER2-directed therapy for gastric cancer in Asian populations, including examination of how outcomes in Chinese patients compare with global trial populations. He has investigated Chinese-specific gastric cancer genomic characteristics, treatment patterns, and outcomes in the REAL-3 and other Chinese gastric cancer trials, and contributed to regional treatment guideline development. His work at one of China's most prominent cancer centers has influenced oncology practice across mainland China and informed Asia-specific cancer treatment approaches.